Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: COVID-19.
- Who it may be relevant to
- Registry conditions: Breast Cancer, Radiation Pneumonia, COVID-19. Basic parameters: 18 years — 80 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Correlation Between COVID-19 and Radiation Pneumonitis in Breast Cancer: A Historical Cohort Study
Overview
This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients.
Detailed description
This study was designed as a single-center retrospective analysis aimed at investigating whether COVID-19 infection increases the risk or burden of radiation-induced pneumonitis in breast cancer patients. Breast cancer patients who underwent radiotherapy at the Cancer Center of Zhejiang Hospital between January 1, 2021, and June 30, 2024, were screened for eligibility. Patients who met the inclusion criteria were identified through the hospital information system, and their clinical records were reviewed. Follow-up was conducted via telephone interviews.
Interventions
- Other COVID-19
The COVID-19 infection situation was used as an intervention measure, and the cohort was divided into groups.
Primary outcome measures
- Radiation Pneumonitis Situation [Time frame: From January 2021 to June 2024]
Eligibility criteria
Inclusion criteria
- patients with pathologically or cytologically confirmed primary breast cancer,
- aged 18 years or older but younger than 80 years,
- with complete and reliable medical records,
- for those with COVID-19 infection, documented evidence of a positive test result.
Exclusion criteria
- concomitant pulmonary malignancies,
- a history of prior thoracic radiotherapy,
- concurrent pulmonary infections other than COVID-19 during radiotherapy,
- missing key data with loss to follow-up,
- or any other condition considered unsuitable for enrollment by the investigators.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Zhejiang Hospital, Department of Oncology, Hangzhou, China, 310030 — Hangzhou
Identifiers
NCT: NCT07188116 · COBRA-001